Aprogen Medicines Inc (007460) Fair Value & Analysis
Industrials · KR · Market cap 69.4B KRW
Fair value as of: Jun 26, 2026
Analysis
Aprogen Medicines Inc (007460) currently trades at 2,385 KRW, while our model-based Fair Value estimate is 4,770 KRW — implying the stock looks roughly 100.0% undervalued today. We read business quality at 80/100 (high quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Aprogen Medicines Inc. designs, manufactures, and maintains plant facilities for steelwork, petrochemistry, shipbuilding, power plant, and LNG base industries in South Korea. The company also offers thermal and cold spray services; and clad rolls, clad plates, wear plates, clad pipes and fittings, and plasma transferred arcs. In addition, it provides Nukon system, a special heat-preservation system that keeps the pipe facility of the internal equipment of the containment building working safely in the pressurized water reactor power plant; foamglas, a cellular glass insulation product; and fireproof insulation works in the POSCO furnaces and boilers. The company was formerly known as Aprogen KIC Inc. and changed its name to Aprogen Medicines Inc. April 2021. Aprogen Medicines Inc. was founded in 2000 and is based in Seongnam-si, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Aprogen Medicines Inc (007460) undervalued?
What is the fair value of 007460?
What is the quality score of 007460?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.